What is the appropriate weight‑based dosing of valacyclovir for children for herpes simplex, varicella, and shingles, including renal adjustment recommendations?

Valacyclovir Dosing for Pediatric Herpes Simplex, Varicella, and Zoster Infections

Valacyclovir is FDA-approved only for chickenpox (ages 2–17 years) and cold sores (ages ≥12 years) in children; for all other pediatric HSV and VZV indications, acyclovir remains the standard of care with established weight-based dosing. 1

FDA-Approved Pediatric Indications for Valacyclovir

Cold Sores (Herpes Labialis) – Ages ≥12 Years

• 2 grams orally twice daily for 1 day (12 hours apart) 1
• Initiate at the earliest symptom (tingling, itching, burning) 1

Chickenpox (Varicella) – Ages 2 to <18 Years

• 20 mg/kg orally three times daily for 5 days (maximum 1 gram per dose) 1
• Start at the earliest sign or symptom 1
• This dose produces acyclovir exposures approximately 50% higher than adult acyclovir 800 mg five times daily and roughly double the exposure seen with acyclovir 20 mg/kg four times daily in children 1

Extemporaneous Oral Suspension Preparation

• Valacyclovir suspension (25 mg/mL or 50 mg/mL) can be compounded from 500-mg tablets using cherry flavor and Suspension Structured Vehicle USP-NF 1
• Prepare in 100-mL lots per USP-NF instructions 1

Off-Label Use: Herpes Simplex Infections

Valacyclovir has limited pediatric data for HSV; acyclovir remains the evidence-based choice. 2

Mucocutaneous HSV (Genital Herpes, Gingivostomatitis)

• Acyclovir is preferred: 20 mg/kg orally (max 400 mg) three times daily for 5–14 days in children <45 kg 2, 3
• Valacyclovir 1 gram orally twice daily is approved only for adults/adolescents; no pediatric formulation or dosing data exist 2
• A pharmacokinetic study showed valacyclovir 10 mg/kg twice daily in children aged 1–11 years produced acyclovir exposures 33% lower than adults receiving 500 mg twice daily 1, 4

Severe or Disseminated HSV (Non-Neonatal)

• Acyclovir 10 mg/kg IV every 8 hours for 21 days for CNS or disseminated disease 3, 5
• Alternative: 500 mg/m² IV every 8 hours (equivalent exposure) 5
• Repeat CSF HSV DNA PCR at days 19–21; continue acyclovir until negative 3, 5

Neonatal HSV (Birth to 1 Month)

• CNS or disseminated disease: acyclovir 20 mg/kg IV every 8 hours for 21 days 3, 5
• Skin/eye/mouth disease: acyclovir 20 mg/kg IV every 8 hours for 14 days 3, 5
• Valacyclovir is not recommended for neonatal suppressive therapy because efficacy cannot be extrapolated from acyclovir 1

Off-Label Use: Herpes Zoster (Shingles)

Valacyclovir is not FDA-approved for pediatric zoster; acyclovir is the standard. 1

Immunocompetent Children

• Acyclovir 20 mg/kg orally (max 800 mg) four times daily for 7–10 days 2, 3
• Start within 48–72 hours of rash onset 3

Immunocompromised Children

• Acyclovir 10 mg/kg IV every 8 hours for severe immunosuppression or complicated disease 2
• Oral acyclovir 20 mg/kg (max 800 mg) four times daily for 7–10 days if mild-to-moderate immunosuppression 2

VZV Retinitis (Acute Retinal Necrosis)

• Acyclovir 10 mg/kg IV every 8 hours for 10–14 days, followed by oral valacyclovir 1 gram three times daily (or acyclovir 20 mg/kg) for 4–6 weeks 2
• This regimen applies only to older children able to receive adult dosing 2

Renal Dose Adjustments

Valacyclovir requires dose reduction in renal impairment; specific pediatric adjustments are not established. 1

• The FDA label states dosage reduction is recommended but provides no pediatric-specific creatinine clearance-based table 1
• For acyclovir (the active metabolite), pharmacokinetic modeling shows clearance increases with creatinine clearance and post-menstrual age 6
• In neonates with systemic HSV infection, volume of distribution increases nearly 3-fold, requiring individualized dosing 6
• Practical approach: Use acyclovir with established renal dosing tables rather than valacyclovir in children with renal impairment 7

Safety Considerations

Nephrotoxicity

• Up to 20% of children receiving IV acyclovir develop reversible crystalluria-related nephropathy, typically after 4 days 3
• Maintain adequate hydration and monitor renal function throughout therapy 3

Hematologic Effects

• Neutropenia occurs in up to 46% of neonates on long-term oral acyclovir suppression but is usually self-limited 5

Age-Specific Pharmacokinetics

• Infants aged 1–3 months receiving valacyclovir 25 mg/kg have 30% higher peak concentrations and 60% higher total exposure than older children 1, 4
• A dosing recommendation cannot be made for infants <3 months because of decreased clearance 4

Acyclovir-Resistant HSV/VZV

Foscarnet is the treatment of choice for acyclovir-resistant infections. 2, 3, 5

• Foscarnet 40 mg/kg IV every 8 hours or 60 mg/kg IV every 12 hours 2, 3, 5
• Infuse slowly over 2 hours with saline fluid loading to reduce renal toxicity 5
• Adjust dose for renal insufficiency 5

Key Clinical Pitfalls

• Do not extrapolate adult valacyclovir dosing to young children: pharmacokinetic studies show 10 mg/kg twice daily produces subtherapeutic exposures compared with adult regimens 1, 4
• Avoid valacyclovir for recurrent genital herpes in children <12 years: insufficient clinical data exist, and efficacy cannot be extrapolated from adults 1
• Do not use valacyclovir for neonatal HSV suppression: it is not approved, and efficacy data are lacking 1
• Recognize augmented renal clearance: children with eGFR >250 mL/min/1.73 m² may require acyclovir 15–20 mg/kg IV every 6 hours to maintain therapeutic concentrations 7